HBV DNA quantitative measures the amount of hepatitis B virus genetic material (viral load) in the blood, usually reported in IU/mL. It reflects infection activity and infectivity, helps stage disease, guide treatment decisions, and monitor response to antiviral therapy. Low values suggest controlled or inactive infection; rising or high levels indicate active viral replication and need for clinical assessment.

HBV DNA is reported in IU/mL; levels above 2,000 IU/mL are generally considered high and clinically significant, especially in HBeAg‑negative patients. Levels above 20,000 IU/mL are often labeled very high and typically indicate active viral replication and greater risk of liver damage. Persistent elevation usually prompts further evaluation and consideration of antiviral treatment alongside ALT and fibrosis assessment.

Cost varies by country, lab and assay. Typical private prices: India about ₹1,500–₹6,000; United States roughly $50–$300 (often covered by insurance); United Kingdom usually provided free on the NHS or £40–£150 privately. Public health systems often cover HBV DNA testing; individual out‑of‑pocket costs depend on the facility, assay sensitivity and insurance—check with your laboratory or provider for exact pricing.

Normal (negative) result is undetectable hepatitis B virus (HBV) DNA, typically below the assay’s lower limit of detection (commonly <10–20 IU/mL). Detectable viral load (≥20 IU/mL) indicates infection; interpretation depends on level — >2,000 IU/mL is often clinically relevant and >20,000 IU/mL suggests high viral replication and greater liver disease risk. Correlate with clinical findings.

Yes. Antiviral drugs can suppress HBV DNA. Nucleos(t)ide analogues such as tenofovir and entecavir, and sometimes interferon, reduce viral replication to undetectable levels, lowering liver damage and transmission risk. They usually do not eliminate cccDNA in infected liver cells, so long-term or lifelong therapy and monitoring are often required; complete eradication is rare.

Hep B quantitative is a blood test that measures hepatitis B virus DNA (viral load) and is reported in IU/mL (or copies/mL). It shows how actively the virus is replicating, guiding decisions about starting or changing antiviral treatment, assessing infectivity, and monitoring response or relapse. Higher values mean more replication and greater infectiousness; undetectable or low levels indicate effective suppression.